Dvl-1, short for Dishevelled-1, is a crucial intracellular protein involved in the Wnt signaling pathway, a cascade fundamental to numerous cellular processes including embryonic development, cell proliferation, and fate determination. Dvl-1 is a part of the larger Dishevelled family of proteins, which also includes Dvl-2 and Dvl-3. When Wnt ligands bind to their cell surface receptors, Frizzled and LRP (lipoprotein receptor-related protein), it leads to the activation of Dvl-1. Subsequently, Dvl-1 plays a role in inhibiting the degradation of β-catenin, a key effector in the Wnt pathway. This allows β-catenin to accumulate in the cytoplasm and eventually translocate to the nucleus, where it regulates the transcription of target genes. Given its pivotal role in the Wnt signaling cascade, Dvl-1 emerges as a central player in translating extracellular signals into transcriptional outcomes.
Activators of Dvl-1 are molecules or compounds that enhance the activity or expression of the Dvl-1 protein. These activators can function by promoting the interaction of Dvl-1 with other Wnt pathway components, by stabilizing its structure, or by increasing its expression at the transcriptional or translational levels. The presence of Dvl-1 activators can amplify the Wnt signaling response, thereby influencing the myriad of cellular processes governed by this pathway. Diving deeper into the domain of Dvl-1 activators offers an understanding of the intricate modulations of Wnt signaling at the intracellular level. As research continues to unravel the complexities of cell signaling cascades, the role of Dvl-1 and its activators is increasingly acknowledged, emphasizing the nuanced interplay of proteins that dictate cellular responses to external cues.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium inhibits GSK-3β, a kinase that negatively regulates the Wnt pathway. By inhibiting GSK-3β, Wnt signaling can be activated, potentially influencing DVL-1 expression. | ||||||
SKL2001 | 909089-13-0 | sc-507410 | 10 mg | $123.00 | ||
This compound directly activates the Wnt/β-catenin pathway by stabilizing β-catenin, potentially influencing DVL-1 expression. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
A GSK-3β inhibitor that activates Wnt/β-catenin signaling, potentially influencing DVL-1 expression. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Another GSK-3β inhibitor that can activate Wnt signaling, potentially influencing DVL-1 expression. | ||||||
JW 55 | 664993-53-7 | sc-364517 sc-364517A | 10 mg 50 mg | $172.00 $726.00 | ||
Acts by inhibiting the interaction between β-catenin and its coactivator, leading to suppression of the Wnt pathway and potential reduction in DVL-1 expression. | ||||||
KY02111 | 1118807-13-8 | sc-397043 sc-397043A | 5 mg 25 mg | $79.00 $336.00 | ||
Promotes degradation of β-catenin, leading to suppression of the Wnt pathway and potential reduction in DVL-1 expression. | ||||||